Alana Iglewicz1, Katherine Morrison2, Richard A Nelesen3, Tingting Zhan4, Boris Iglewicz5, Nathan Fairman6, Jeremy M Hirst3, Scott A Irwin7. 1. Department of Psychiatry and Moores Cancer Center, University of California, La Jolla, CA (AI, RAN, JMH, SAI); San Diego Veterans Affairs Healthcare System, La Jolla, CA (AI). 2. Department of Internal Medicine and Inpatient Palliative Medicine Service, University of Colorado, Aurora, CO (KM). 3. Department of Psychiatry and Moores Cancer Center, University of California, La Jolla, CA (AI, RAN, JMH, SAI). 4. Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA (TZ). 5. Department of Statistics, Temple University, Philadelphia, PA (BI). 6. Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA (NF). 7. Department of Psychiatry and Moores Cancer Center, University of California, La Jolla, CA (AI, RAN, JMH, SAI). Electronic address: sirwin@ucsd.edu.
Abstract
BACKGROUND: Depression is prevalent in patients receiving hospice care. Standard antidepressant medications do not work rapidly enough in this setting. Evidence suggests that ketamine rapidly treats treatment refractory depression in the general population. Ketamine׳s role for treating depression in the hospice population warrants further study. METHODS: A retrospective medical record review of 31 inpatients receiving hospice care who received ketamine for depression on a clinical basis was conducted. The primary outcome measure was the Clinical Global Impression Scale, which was used retrospectively to rate subjects׳ therapeutic improvement, global improvement, and side effects from ketamine over 21 days. Additionally, time to onset of therapeutic effect was analyzed. RESULTS: Using the Clinical Global Impression Scale, ketamine was found to be significantly therapeutically effective through the first week after ketamine dosing (p < 0.05), with 93% of patients showing positive results for days 0-3 and 80% for days 4-7 following ketamine dosing. Patients experienced global improvement during all 4 studied time periods following ketamine dosing (p < 0.05). Significantly more patients had either no side effects or side effects that did not significantly impair functioning at each of the 4 assessed time periods following ketamine dosing (p < 0.05). Additionally, significantly more patients experienced their first therapeutic response during days 0-1 following ketamine dosing (p < 0.001) than during any other time period. CONCLUSIONS: These data suggest that ketamine may be a safe, effective, and rapid treatment for clinical depression in patients receiving hospice care. Blinded, randomized, and controlled trials are required to substantiate these findings and support further clinical use of this medication in hospice settings.
BACKGROUND:Depression is prevalent in patients receiving hospice care. Standard antidepressant medications do not work rapidly enough in this setting. Evidence suggests that ketamine rapidly treats treatment refractory depression in the general population. Ketamine׳s role for treating depression in the hospice population warrants further study. METHODS: A retrospective medical record review of 31 inpatients receiving hospice care who received ketamine for depression on a clinical basis was conducted. The primary outcome measure was the Clinical Global Impression Scale, which was used retrospectively to rate subjects׳ therapeutic improvement, global improvement, and side effects from ketamine over 21 days. Additionally, time to onset of therapeutic effect was analyzed. RESULTS: Using the Clinical Global Impression Scale, ketamine was found to be significantly therapeutically effective through the first week after ketamine dosing (p < 0.05), with 93% of patients showing positive results for days 0-3 and 80% for days 4-7 following ketamine dosing. Patients experienced global improvement during all 4 studied time periods following ketamine dosing (p < 0.05). Significantly more patients had either no side effects or side effects that did not significantly impair functioning at each of the 4 assessed time periods following ketamine dosing (p < 0.05). Additionally, significantly more patients experienced their first therapeutic response during days 0-1 following ketamine dosing (p < 0.001) than during any other time period. CONCLUSIONS: These data suggest that ketamine may be a safe, effective, and rapid treatment for clinical depression in patients receiving hospice care. Blinded, randomized, and controlled trials are required to substantiate these findings and support further clinical use of this medication in hospice settings.
Authors: Nancy DiazGranados; Lobna A Ibrahim; Nancy E Brutsche; Rezvan Ameli; Ioline D Henter; David A Luckenbaugh; Rodrigo Machado-Vieira; Carlos A Zarate Journal: J Clin Psychiatry Date: 2010-07-13 Impact factor: 4.384
Authors: Laura E Phelps; Nancy Brutsche; Jazmin R Moral; David A Luckenbaugh; Husseini K Manji; Carlos A Zarate Journal: Biol Psychiatry Date: 2008-11-08 Impact factor: 13.382
Authors: Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew Journal: Biol Psychiatry Date: 2010-01-15 Impact factor: 13.382
Authors: Nicolas A Nuñez; Boney Joseph; Mehak Pahwa; Ashok Seshadri; Larry J Prokop; Simon Kung; Kathryn M Schak; Jennifer L Vande Voort; Mark A Frye; Balwinder Singh Journal: Psychopharmacol Bull Date: 2020-09-14
Authors: Linda Nguyen; Patrick J Marshalek; Cory B Weaver; Kathy J Cramer; Scott E Pollard; Rae R Matsumoto Journal: Neuropsychiatr Dis Treat Date: 2015-10-14 Impact factor: 2.570
Authors: Eduard Falk; Daniel Schlieper; Patrick van Caster; Matthias J Lutterbeck; Jacqueline Schwartz; Joachim Cordes; Ina Grau; Peter Kienbaum; Martin Neukirchen Journal: BMC Palliat Care Date: 2020-01-03 Impact factor: 3.234